Introduction: The TNM classification for lung cancer, originally designed for NSCLC, is applied to staging of bronchopulmonary carcinoid tumors. The validity of the eighth edition of the staging system for carcinoid tumors has not been assessed. In this study, we evaluated its prognostic accuracy by using data from a large national population-based cancer registry.
Introduction
Carcinoid tumors of the lung comprise 20% to 30% of all neuroendocrine tumors (NETs) and roughly 1% to 2% of lung malignancies. However, the incidence of bronchopulmonary carcinoid tumors has been rising over the course of the past 30 years, 1 which may reflect increasing detection and identification of carcinoids with the use of cross-sectional imaging and bronchoscopy. On the morphological spectrum, carcinoids are classified as typical low-grade (<2 mitoses per 2 mm 2 of viable tumor, lacking necrosis) or atypical intermediate-grade (2-10  mitoses per 2mm 2 and/or foci of necrosis) tumors that are larger than 5 mm. [2] [3] [4] Carcinoid tumors lacking necrosis and mitotic activity that are 5 mm or smaller are defined as carcinoid tumorlets. Tumorlets are most commonly incidental findings, but they may also occur in the rare but distinct entity diffuse idiopathic neuroendocrine cell hyperplasia (DIPNECH), which is considered to be a precursor condition for the development of carcinoid tumors.
Because of their relatively uncommon nature, no specific staging system exists for these cancers. Although designed for NSCLC, the TNM classification system has been applied to bronchopulmonary carcinoids since 2010, and it is the approach that is currently recommended by both the European Neuroendocrine Tumor Society and North American Neuroendocrine Tumor Society. 5, 6 The eighth edition of the TNM cancer staging system, 7 which was recently amended after analysis of the International Association for the Study of Lung Cancer database, 8 came into effect in the United States on January 1, 2018. There are significant changes from the seventh edition 9 in the definition of the T and M descriptors, as well as in the assignment of stage groupings. These changes were recommended on the basis of analyses performed in NSCLC, [10] [11] [12] and to our knowledge, validation for carcinoid tumors has not yet been performed.
In this study, we used population-based data from a national cancer registry to investigate the relationship between TNM staging classification and survival for typical and atypical carcinoid tumors.
Methods

Study Population
Patients were identified from the Surveillance, Epidemiology, and End Results (SEER) database, which is a cancer incidence registry that includes more than 30% of the U.S. population. From the November 2016 release of SEER, 13 which included data collected up to 2013, we selected typical (histological code 8240) and atypical (HISTO3V 8249) bronchopulmonary carcinoid tumors (PRIMSITE C340-C343, C348, and C349) diagnosed between 2000 and 2013. Adults age18 years or older with pathological confirmation of a lung NET were included in the study. We also included those with carcinoid tumorlets (<0.5 cm). Only patients whose cancer was diagnosed after 2000 were included, as the current criteria for pathological distinction between typical and atypical carcinoid tumors were proposed in 1998 14 and was incorporated into the WHO classification in 1999. 4 The cases of typical bronchopulmonary carcinoid tumors will henceforth be referred to as the typical cohort, and the atypical tumors will be referred to as the atypical cohort. Patients were excluded if the diagnosis was made at autopsy or by death certificate, if there was history of another cancer, or if there was missing staging information. Demographic data, including age, sex, race/ethnicity, and marital status, were obtained from SEER. Data on primary tumor size, local extension, lymph node involvement, and presence of distant metastases were used to determine clinical stages according to the eighth edition of the TNM staging system. Because of a lack of available data in SEER regarding the number of extrathoracic metastases (single versus multiple), M1b and M1c tumors were analyzed as a single group (henceforth denoted as M1bþc). Because of this, stages IVA and IVB were grouped together for analysis (denoted as stage IV). Because of the small numbers of tumors in stage IIIC (n ¼ 4), stages IIIB and IIIC were also combined for analysis (henceforth denoted as IIIBþC).
The primary outcome of this study was death from lung NET. To account for competing risks from other causes of death, we used cumulative incidence function (CIF) methods to estimate disease-specific survival (DSS) at 10 years by calculating the complement of the cumulative incidence of death due to lung NET. We then plotted curves comparing groups of interest by 1-CIF. Time to events of interest was calculated from date of diagnosis until death or last follow-up. Cause of death as specified in the death certificate was available from SEER. Deaths not due to a lung CIF were classified as competing events.
Statistical Analysis
Descriptive statistics were used for demographic and clinical characteristics of the study population. We evaluated cumulative incidence of lung NET death by stage by using CIF analyses. Cumulative incidence of death due to a lung NET was compared by stage using the methods proposed by Pepe and Mori. 15 Multivariable CIF competing risks analyses were also performed by using the Fine-Gray method with adjustment for age, sex, race/ethnicity, marital status, histological type, and surgical treatment. 16 All analyses were performed with SAS Studio software (SAS Institute Inc., Cary, NC), with two-sided p values less than or equal to 0.05 considered significant. As a population-based study with no identifiable patient data, our study was exempt from institutional review board review.
Results
In the SEER database, 5405 patients who met the inclusion criteria were identified. Of these, 760 patients (14%) were excluded on account of incomplete staging information, leaving a final study cohort of 4645 patients ( Fig. 1 ). Of the study cohort patients, 67% were female and 81% were white, with a mean age of 58 years (SD, 15 years [ Table 1 ]). Most cases were stage I (65%), with stage IA (IA1-IA3) accounting for 51% and stage IB accounting for 14% of all cases. Stages IIA, IIB, IIIA, IIIBþC, and IV accounted for 3%, 9%, 13%, 2%, and 8% of cases, respectively. Overall, 4009 patients (86%) underwent surgical treatment, with the most common modalities being lobectomy (58%) and local resection (22%). Most patients with nonmetastatic disease underwent surgical treatment (90%). The median duration of follow up was 54 months.
Survival Analysis
Typical Carcinoids. Within the typical cohort (n ¼ 4254), T status was a significant predictor of DSS (p < 0.001 [ Fig. 2A] ). Except for differences in DSS between T1a and T1b status (p ¼ 0.037) and between T2a and T2b status (p < 0.001), the consecutive curves overlapped. Estimates of 10-year DSS as calculated by 1-CIF are outlined in Table 2 . The categories T1a, T1b, and T1c had 10-year DSS rates of 97%, 96%, and 93%, respectively. T2a/T2b had a DSS rate of 91%/75%, and T3/T4 had a DSS rate of 76%/ 79%. Significant differences in DSS were found with increasing N status (p < 0.001 [ Fig. 2B] ). N0 status conferred a DSS rate of 94.3% compared with those for N1 and N2 (rates at 10 years of 76% and 56%, respectively). N3 status had a DSS rate of 0%, with no patients surviving beyond 80 months. Overall, M status was also a significant predictor of DSS (p < 0.001 [ Fig. 2C] ). There was no significant difference in DSS between M0 and M1a (p ¼ 0.075); M0 had a DSS estimate of 93%, and M1a had a DSS rate of 87%. DSS declined steeply to 28% for M1bþc. On further analysis of patients with M1a disease, 101 of 171 (59%) had multifocal disease, presenting with separate nodules in the contralateral lung.
Significant differences in DSS were found according to stage category (p < 0.001 [ Fig. 3A] ). However, on comparison of adjacent stage categories, no adjacent stages were significantly different from one other. The 10-year DSS rates were 98%, 97%, 96%, and 94% for stages IA1, IA2, IA3, and IB, respectively. For stages IIA and IIB, the DSS rates were 85% and 86%, and for IIIA, the DSS rate was 85%. This difference decreased to 49% and 59% for stages IIIBþC and IV, respectively. Analysis of combined stages gave 10-year DSS estimates of 96%, 85%, 81%, and 59%, for stage I, II, III and IV, respectively. These combined stages were significantly different from their adjacent groups (p < 0.001 [ Fig. 3B] ).
Atypical carcinoids. For atypical carcinoids (n ¼ 391), worsening DSS was demonstrated with increasing T Figure 1 . Selection of study cohort from Surveillance, Epidemiology, and End Results database. HISTO3V, Histologic Type ICD-O-3; NOS, not otherwise specified; PRIMSITE, primary site. status (p < 0.001 [ Fig. 2D]) . Again, there were overlaps in DSS curves between T categories. A significant difference in DSS was found between T1a and T1b (p ¼ 0.002), T1c and T2a (p < 0.001), T2b and T3 (p < 0.001), and T3 and T4 (p < 0.001). The categories T1a, T1b, and T1c had 10-year DSS rates of 81%, 80%, and 85%, respectively. T2a and T2b had DSS rates of 64% and 61%, respectively. T3 and T4 had DSS rates of 31% and 42%, respectively. N status was a significant predictor of DSS (p < 0.001 [ Fig. 2E] ). The N0 group had a DSS rate of 83%, decreasing to 57%, 28%, and 33% for N1, N2, and N3, respectively. The effect of M status was significant overall (p < 0.001 [ Fig. 2F]) , with M0 conferring a DSS rate of 73%. The 10-year DSS estimate was 0% for the M1a group (n ¼ 7), with no patients surviving beyond 60 months. M1bþc had a DSS of 12%.
Prognostic stage had a significant effect on DSS (p < 0.001 [ Fig. 3C ], but a comparison of adjacent stage categories did not reveal significant differences between the adjacent stages 1A1 and 1A2 (p ¼ 0.057) or between IIA and IIB (p ¼ 0.54). The DSS rates were 83% and 91% for stages IA1 and IA2, respectively. There were no events in the stage IA3 group. Stage IB had a DSS rate of 66%. Stages IIA, IIB, IIIA had DSS rates of 88%, 73%, and 58%, respectively. The rate decreased for stages IIIBþC (24%) and stage IV (19%). This pattern reflects a similar pattern observed in typical carcinoids, where stages IIIBþC and IV had much lower 10-year DSS estimates than IIIA did. Cumulative incidence of lung NET death was significantly different across stage categories (p < 0.001 [see Fig. 3A and B]), ranging from 17% (stage IA1) to 81% (stage IV). On combined stage analysis, significant differences between all adjacent stage categories were found (Fig. 3D) . This analysis yielded DSS rates of 88%, 76%, 48%, and 19% for stages I, II, III, and IV, respectively.
Adjusted Analyses
We also observed overlaps in hazard ratio (HR) estimates for disease-specific mortality between the adjacent TNM and stage categories (Table 3) . stage IIIBþC, HR ¼ 27.2 and 95% CI: 9.5-77.6; and for stage IV, HR ¼ 22.5 and 95% CI: 7.8-58.9). The HR estimates of combined stage categories revealed a clearer pattern, with combined stage II, stage III, and stage IV conferring HRs of 3.8 (95% CI: 2.6-5.6), 4.3 (95% CI: 3.0-6.1), and 9.0 (95% CI: 6.1-13.1), respectively, in comparison with stage I.
Atypical carcinoids. For atypical carcinoids, no significant differences in DSS were found for any T status compared with for the T1a group (see Table 3 
Discussion
The eighth edition of the TNM staging system for lung cancer has not yet been validated for lung carcinoids. Furthermore, because of the uncommon incidence of lung carcinoids and refinement of the definition of typical and atypical carcinoid in the 1999 WHO pathological classification, data on the natural history of these tumors have been limited, especially in the case of atypical carcinoids. In this study, we used population- based data to demonstrate that the eighth edition of the TNM staging system predicts outcomes to a degree in both typical and atypical lung carcinoids. Although the combined stages (I versus II, II versus III, and III versus IV) demonstrate greater separation in DSS outcomes as calculated using competing risks methods, combined stage HR CIs and subcategories of the stage groups demonstrate substantial overlap and do not show significant differences in DSS. These findings may limit the usefulness of the TNM staging system, particularly in stages II and III. To our knowledge, this is the first survival analysis for carcinoid tumors of the lung that has been performed by using the eighth edition of the TNM staging system. The most significant changes in the eighth edition include the decrease in size boundaries between categories, especially in smaller tumors. For example, in the seventh edition of the TNM staging system, the category T2 includes tumors with diameters of 3 to 7 cm, in contrast to inclusion of only those with diameters of 3 to 5 cm in the eighth edition. The boundaries within the category T1 have also been shifted (e.g., the upper limit for T1a has changed from 2 cm to 1 cm), which accounts for the higher DSS in our study than in similar studies conducted earlier. [17] [18] [19] This stage migration should be kept in mind when interpreting the results of this and future studies. We have also separated the typical from the atypical cohort, which previous studies have not been able to achieve on account of limited numbers. Finally, previous studies have had different exclusion criteria, outcomes, or population sampling, which may help explain the apparent discrepancies in survival.
However, a trend toward better outcomes of neuroendocrine tumors that is not attributable to stage migration has previously been reported. In particular, Quaedvlieg et al. found a significant improvement in survival for patients with dates of diagnosis after 1992, in patients with metastatic carcinoid disease. 20 A later study in the United States replicated the results obtained by Quaedvlieg et al. using SEER by using an earlier cutoff (1987) . 21 It is possible that the introduction of octreotide in 1987 was responsible for stabilization of metastatic disease, resulting in improved survival estimates.
In addition, current staging assigns any case with metastasis to stage IV. Our analysis demonstrated that for typical carcinoids, there were large differences in DSS in patients with metastases depending on the M subcategory. Interestingly, M1a had a DSS approaching that of M0 and a nonsignificant HR in comparison with that of M0, which was markedly better than that for the M1bþc group. The high proportion of multifocal tumors in the M1a group in conjunction with high rate of survival has led to the suggestion that DIPNECH may be the underlying disease for these cases. 18 Tumorlets are commonly detected incidentally in the lung. As they are considered T1a, they may improve outcomes for these early stages. A distinct but much rarer entity with diffuse tumorlets, DIPNECH is a preinvasive lesion found incidentally or in association with obstructive lung disease and carcinoid tumors. 22, 23 DIPNECH, as defined by the WHO is "a generalized proliferation of pulmonary neuroendocrine cells that may be confined to the mucosa of airways (with or without luminal protrusion), may invade locally to form tumorlets, or may develop into carcinoid tumors." It has been recognized as a distinct condition since 1992. 24 Outcome data are therefore limited for these patients.
The largest series to date (N ¼ 30 patients [all female]), described one death from DIPNECH as a result of obliterative bronchiolitis and overall heterogeneous progression of obstructive lung disease. 25 A recent metaanalysis identified only two DIPNECH-attributed deaths among 114 patients for whom follow-up data were available in the literature. 26 Furthermore, only one case within this cohort progressed to a carcinoid tumor, though according to a study by Marchevsky et al., 53% of patients with DIPNECH present with a synchronous carcinoid tumor. 27 The strengths of our study include our large sample size and the use of a population-based registry, which allowed us to reflect a varied population and removed referral bias for this uncommon tumor. Unlike in previous studies, we also restricted our cohort to those whose tumors were diagnosed after 2000. Given the change in the histological definition of atypical carcinoid tumors at this time, our selected cohort is more likely to accurately reflect the current histological definitions.
A limitation of this study is that we did not have information sufficient for the updates to the TNM staging system. The SEER database does not specify the number of extrathoracic metastases; hence, we were not able to identify patients with M1b versus M1c disease. In addition, the small numbers in some of the subgroups, especially the subgroup of patients with atypical carcinoids, limited our estimation of survival in these groups. Despite these limitations, our study provides valuable information regarding long-term survival outcomes in carcinoid tumors, especially in the absence of validation of the updated staging system.
In conclusion, the eighth of the TNM staging system, which uses the combined stage categories, provides reliable prognostic discrimination of outcomes in bronchopulmonary neuroendocrine tumors. However, subcategories of the new TNM classification do not provide adequate separation from their neighbors, and further study is warranted to tailor the staging system for lung carcinoid tumors. 
